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Abstract
Background—Hepatitis E (HEV) is an emerging cause of viral hepatitis mainly transmitted 
through the fecal-oral route. Residents of the Kibera slum of Nairobi, Kenya are at risk for fecal-
orally transmitted infections.
Objective—To quantify the incidence and prevalence of HEV infection among acute febrile 
illness (AFI) cases using a population-based infectious disease surveillance network.
Study Design—Cross-sectional serum samples from AFI case-patients between 2009 and 2012 
were matched to the age and gender distribution of the Kibera population and tested by IgM and 
IgG enzyme immunoassays (EIA) and nucleic acid testing (NAT). Serum from healthy residents 
was also tested by EIA.
Results—Of the 482 AFI serum samples tested, 124 (25.7%) and 182 (37.8%) were IgM and 
IgG reactive, respectively. On multivariate analysis, IgM reactivity was associated with HIV (RR 
1.66, 95%CI 1.07, 2.60; p=0.024) while IgG reactivity was associated with increasing age 
(p<0.001) and HIV (RR 1.93, 95%CI 1.52, 2.46; p<0.001). AFI case-patients were more likely to 
be IgM (p=0.002) and IgG (p<0.001) reactive compared to healthy residents. The seroincidence by 
HEV-specific IgM was 84.0 per 1,000 person years, however, all 482 samples were negative by 
NAT.
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Conclusions—Serologic evidence for HEV in Kibera suggests a high burden of infection, but 
NAT did not confirm HEV viremia. Additional testing is needed to determine whether EIAs are 
susceptible to false positivity in undifferentiated AFI populations before their widespread use.
Background
Globally, there are an estimated 20 million hepatitis E virus (HEV) infections, 3 million 
cases of symptomatic HEV, and 70,000 HEV-related deaths each year [1]. In East Africa, 
large outbreaks have been documented, most recently in Uganda, South Sudan, and Kenya 
[2–4]. While data on HEV endemicity in this region is scarce, an acute jaundice surveillance 
system in Uganda found that 42% of cases were due to HEV infection [5] suggesting that 
HEV may be an under-recognized cause of viral hepatitis in Africa.
Currently, HEV testing consists of identifying HEV-specific host antibodies with enzyme 
immunoassays (EIAs) or HEV RNA through nucleic acid testing (NAT) methods [6]. Both 
IgM and IgG are detectable at the time of symptom onset. IgM wanes after several weeks 
while IgG remains detectable for years. HEV RNA is detectable by NAT in serum or stool 
with peak RNA levels occurring during late incubation and lasting approximately 2–3 weeks 
after symptom onset [6]. NAT validation of IgM EIAs demonstrate a sensitivity and 
specificity that vary from 72–98% and 78–95%, respectively [7].
The clinical presentation of HEV infection varies from asymptomatic illness to fulminant 
hepatitis. The majority of HEV infections are mild with nonspecific symptoms resembling a 
non-specific febrile illness and patients may not necessarily seek health care [6]. Jaundice 
occurs in approximately 40% of cases.
Objective
Determine the incidence and prevalence of HEV infection in a population-based sample of 
undifferentiated acute febrile illness (AFI) cases in Kibera, Kenya.
Study Design
Setting
Kibera, located within the city of Nairobi, is the largest urban slum in Africa. The US 
Centers for Disease Control (CDC) and the Kenya Medical Research Institute (KEMRI) 
have conducted population-based infectious disease surveillance (PBIDS) in Kibera since 
2005 in an area with an estimated population of 25,000–29,000 individuals in 0.37km2 area. 
Due to the high population density and lack of sufficient clean water and proper sanitation, 
fecal-orally transmitted diseases account for a large proportion of the infectious disease 
burden in Kibera [8].
Participants who have resided in Kibera for at least 4 months are eligible for enrollment in 
PBIDS and are visited biweekly for screening. The undifferentiated AFI cohort includes 
participants who either present to a clinic or are detected by household visits and have an 
axillary temperature ≥38.0°C without an obvious source [8]. Each AFI case-patient submits 
blood, stool, and nasopharyngeal samples for clinical diagnosis and research purposes within 
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7 days of onset of illness. The samples are stored at −80°C in freezers with backup 
generators maintained by the CDC.
Specimen Analysis
Serum samples collected between 2009 and 2012 from randomly selected AFI case-patients 
matched by the age and gender distribution of Kibera were tested by EIA and NAT. Each 
sample was tested by EIA in duplicate for IgM and IgG-specific HEV antibodies (DS-EIA-
ANTI-HEV-G, DS-EIA-ANTI-HEV-M. IgM sensitivity (98.0%) and specificity (95.2%) 
[7]). Results were averaged to generate a signal-to-noise ratio with ≥1.0 designated as 
positive per the manufacturer’s recommended cutoff. Each serum sample underwent HEV 
NAT by both reverse transcription and real-time polymerase chain reaction protocols 
developed by CDC [9]. Univariate and multivariate log-binomial regression analysis of 
demographic and EIA data were computed with Stata 13. The total number of AFI cases 
during the study period were used to calculate incidence.
Specimens from healthy residents presenting to the clinic with non-infectious complaints 
were selected by matching the age and gender distribution of Kibera and were tested with 
HEV EIA. Student’s T-test was used to compare the rate of IgM and IgG-reactive subjects in 
the AFI and healthy groups.
Results
Of the 482 AFI case-patients, 51.2% were female, the average age was 20.4 years, 9 
individuals (1.9%) had jaundice, and HIV status was unknown in 293 (60.1%), positive in 34 
(7.1%), and negative in 155 (32.2%). HEV EIA identified 124 (25.7%) IgM reactive and 182 
(37.8%) IgG reactive case-patients. Among HEV EIA reactive samples, the majority were 
weakly reactive for both IgM (median signal-to-noise ratio: 1.4, range: 1.0–5.9) and IgG 
(median signal-to-noise ratio 1.38, range: 1.0–8.3). All samples were negative for HEV 
RNA by both NAT methods.
On univariate analysis, IgM reactivity was associated with female gender (p=0.049) while 
IgG reactivity was associated with older age (p≤0.001) (Table 1). IgM (p=0.003) and IgG 
(p≤0.001) reactivity were both associated with HIV infection. There was no statistically 
significant association between jaundice and IgM (p=0.598) or IgG (p=0.266) reactivity. On 
multivariate log-binomial regression, only HIV was associated with IgM reactivity (RR 1.66, 
95%CI 1.07, 2.60; p=0.024) (Table 2). IgG reactivity was associated with increasing age 
(p<0.001 for trend) and HIV positivity (RR 1.93, 95%CI 1.52, 2.46; p<0.001).
During the study period, there were 25,353 AFI cases accounting for 77,555 person years. 
The HEV IgM seroincidence was estimated to be 84.0 per 1,000 person years while HEV 
IgG prevalence was 37.8%.
The 57 healthy residents tested for comparison had a similar age (p=0.771), gender 
(p=0.342), and HIV status (p=0.661) distribution as the AFI sample. Four samples (7.0%) 
were IgM reactive while 1 sample (1.8%) was IgG reactive. AFI case-patients were more 
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likely to be IgM and IgG reactive than healthy subjects by student’s T-test (p=0.002 and 
p<0.001, respectively).
Discussion
The seroincidence of HEV infection in Kibera among persons with undifferentiated AFI was 
high based IgM EIA reactivity. The HEV seroincidence is similar to rates observed in a 
Bangladeshi cohort [10]. However, reconciling the high rate of IgM positivity with the 
absence of RNA by NAT is challenging as the former may represent false positives while the 
latter may represent false negatives. While the HEV EIA used has favorable performance 
characteristics [7], its validity in undifferentiated AFI is not known. Similarly, while HEV 
NAT is a highly sensitive test with its low limit of detection [11], the absence of HEV RNA 
in itself does not exclude true HEV-specific IgM antibodies.
The absence of HEV RNA in the setting of IgM positivity has been previously noted in both 
a Ugandan acute jaundice syndrome cohort and a Cambodian AFI cohort where only 58% 
and 1.0% of IgM positive cases had detectable RNA, respectively [2, 12]. The investigators 
hypothesized that alternative infectious agents may cause cross-reactivity of HEV EIAs, 
resulting in false positives. Other research has demonstrated EIA cross reactivity between 
EBV and CMV [13–14], hepatitis A [15], and HIV [16–17], suggesting a ‘molecular 
mimicry’ phenomenon. Our findings of a significant association between HIV and HEV 
IgM positivity, lack of HEV RNA, and lower rates of HEV EIA positivity among healthy 
control residents may be suggestive of such a process. The high rate of IgG positivity also 
may suggest a similar phenomenon. Convalescent serum samples were not available for 
confirmatory testing of this hypothesis.
Previous studies in the East African region demonstrate that respiratory viruses account for 
the majority of febrile illness [18–19], malaria was an infrequent cause of fever in Kenya 
(≤5%) [19–20], and viral hepatitis was rare [18]. Unfortunately, data on these concomitant 
infections were not available for our analysis.
To further elucidate the validity of the HEV IgM EIA, we propose testing of AFI incident 
and convalescent sera to determine if there is a change in titers of IgM after initial positivity 
and persistence of IgG positivity expected in true HEV infections. HEV immunoblot may 
also be used to validate the IgM EIA given its high specificity [21]. In addition to further 
testing for concomitant infections to assess for molecular mimicry, plaque reduction 
neutralization testing can be used to identify antibodies against both HEV and other 
infections.
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• Hepatitis E (HEV) diagnosis consists of indirect testing with enzyme 
immunoassays and direct testing with nucleic acid testing (NAT)
• Serologic evidence suggests a high level of HEV infection among persons with 
undifferentiated AFI in Kibera
• NAT did not corroborate a high level of HEV infection among our AFI sample 
population
• Serologic HEV testing in a population with undifferentiated AFI may yield false 
positives due to cross-reactivity from other infectious agents.
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